China, Sept. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Human Embryonic Stem Cell Derived Mesenchymal Stromal Cells for... Read More
China, Sept. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective observational cohort study on the characteristics of sexual dysfunction ... Read More
China, Sept. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Isolation and Identification of Brain-Derived Disease-Specific α-Synuclein in the Bloo... Read More
China, Sept. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Study on Auricular Vagus Nerve Stimulation for Improving Postoperative Sleep After S... Read More
China, Sept. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A randomized controlled trial of transcutaneous tibial nerve stimulation in women with... Read More
China, Sept. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Metagenomic Analysis of Changes in the Ocular Surface Microbiome in Tubulitis Lacrimal... Read More
Singapore, Sept. 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutam... Read More
Singapore, Sept. 28 -- The Health Sciences Authority received information related to the study titled 'An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-086... Read More
Singapore, Sept. 28 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy W... Read More
Singapore, Sept. 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Ve... Read More